QUALCOMM Incorporated (NASDAQ:QCOM) [Trend Analysis] climbed reacts as active mover, shares a gain 0.52% to traded at $65.81 and the percentage gap between open changing to regular change was 0.00%. Qualcomm (QCOM) finally took the wraps off its Snapdragon 835 processor on Tuesday as the company officially reported the specific details about its latest SoC. Alongside, Qualcomm reported the first product to run on the new Snapdragon 835 SoC ODG’s AR/ VR smart glasses, apart from the latest edition of its connected car reference platform, as well as a new reference design for wireless stereo headsets, and new active noise cancellation technology for ultra smallearbuds.
Interestingly, almost all of the specifications of the Qualcomm Snapdragon 835 processor were already leaked in a blog post spotted earlier this week. Qualcomm had previously detailed that the Snapdragon 835 is built on the 10nm FinFET fabrication process by Samsung. The new Snapdragon 835 processor features support for Quick Charge 4.0, and is capable of delivering 27 percent higher performance while consuming 40 percent less power than the Snapdragon 821. Now, Qualcomm has provided further details about the Snapdragon 835. The firm’s current ratio calculated as 3.10 for the most recent quarter. The firm past twelve months price to sales ratio was 4.16 and price to cash ratio remained 5.25. As far as the returns are concern, the return on equity was recorded as 18.70% and return on investment was 11.90% while its return on asset stayed at 11.20%. The firm has total debt to equity ratio measured as 0.37.
Agile Therapeutics, Inc. (NASDAQ:AGRX) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -1.14% to close at $2.60 with the total traded volume of 667556 shares. Law Offices of Howard G. Smith reported an investigation on behalf of investors of Agile Therapeutics, Inc. (AGRX) concerning the Company and its officers’ potential violation of federal securities laws.On January 3, 2017, Agile disclosed statistical information pertaining to its Phase 3 SECURE study analyzing the Company’s combined hormonal contraceptive patch Twirla.
The study, which was initiated at the request of the FDA, comes after the FDA rejected Agile’s initial marketing application back in 2013. The Company cited “positive top-line results” in the study, yet declared that almost 2% of subjects experienced “serious adverse events” including “deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression.” Additionally, 51.4% of subjects opted to discontinue the study. The firm has institutional ownership of 87.90%, while insider ownership included 13.89%. AGRX attains analyst recommendation of 1.50 with week’s performance of -59.60%.